BBH Performance — VanEck Biotech ETF
Data updated: 2026-08-26
BBH returned +7.41% year to date and +33.18% over one year to Jun 2026. Annualised returns are +9.80% over 3 years and +0.61% over 5 years. The fund trailed its Health Care Equity category average: $100 invested three years ago grew to $132, against $138 for the category, and to $133 over one year, against $137. Volatility over the past three years was 16.16% a year. In the 12 months to Jun 2026 the fund lost a net $36.2M, and assets reached $395.55M.
BBH Growth of $100
What $100 invested in VanEck Biotech ETF grew to, compounded from monthly returns reported on SEC Form N-PORT, against the Health Care Equity category average over the same months.
| Period | BBH | Category average |
|---|---|---|
| 1 year (Jul 2025 – Jun 2026) | $133 | $137 |
| 3 years (Jul 2023 – Jun 2026) | $132 | $138 |
| 5 years (Jul 2021 – Jun 2026) | $103 | $121 |
| Since data start (Jul 2019 – Jun 2026) | $162 | $182 |
BBH Trailing Returns
Total returns to Jun 2026, from SEC N-PORT.
| Period | Total return |
|---|---|
| YTD | +7.41% |
| 1 year | +33.18% |
| 3 years (annualised) | +9.80% |
| 5 years (annualised) | +0.61% |
BBH Annual Returns
Calendar-year total returns of VanEck Biotech ETF, compounded from monthly SEC N-PORT returns. Partial years show the months covered.
| Year | Total return |
|---|---|
| 2026 (Jan–Jun) | +7.41% |
| 2025 | +21.14% |
| 2024 | −4.39% |
| 2023 | +3.86% |
| 2022 | −15.12% |
| 2021 | +11.77% |
| 2020 | +22.03% |
| 2019 (Jul–Dec) | +8.25% |
BBH Monthly Returns
Monthly total returns as reported on SEC Form N-PORT.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +3.9% | +0.7% | −5.0% | −1.4% | +1.6% | +7.8% | — | — | — | — | — | — |
| 2025 | +5.4% | −0.5% | −4.4% | −2.8% | −2.9% | +3.2% | +5.8% | +1.9% | +0.3% | +9.3% | +9.1% | −3.8% |
| 2024 | +0.2% | −1.7% | +2.1% | −6.2% | +5.5% | +2.4% | +6.9% | +0.6% | −2.1% | −4.3% | −1.6% | −5.4% |
| 2023 | +4.9% | −6.7% | +3.5% | −1.3% | −3.2% | +0.8% | +3.1% | +1.6% | −4.7% | −7.3% | +5.1% | +9.5% |
| 2022 | −12.8% | −4.7% | +3.2% | −9.7% | +1.1% | −1.4% | +5.8% | −5.6% | −3.6% | +11.7% | +6.9% | −4.3% |
| 2021 | +10.1% | −4.3% | −2.0% | +7.5% | −2.3% | +9.7% | +2.5% | +4.4% | −6.5% | −1.3% | −1.9% | −3.0% |
| 2020 | −5.1% | +1.1% | −4.5% | +16.0% | +8.7% | +1.2% | +1.1% | −2.6% | +0.9% | −5.7% | +10.7% | +0.7% |
| 2019 | — | — | — | — | — | — | −2.5% | −2.3% | −4.2% | +7.1% | +11.6% | −0.7% |
BBH Risk
Risk measures from monthly returns over Jul 2023 – Jun 2026.
- 3-year volatility (annualised): 16.16%
- 3-year Sharpe ratio: 0.33 (vs 4.5% risk-free rate)
- Best month: +9.46% (Dec 2023)
- Worst month: −7.26% (Oct 2023)
BBH Fund Flows
Monthly money in and out of VanEck Biotech ETF, from SEC Form N-PORT.
- 12-month net flow: −$36.2M
- 12-month gross sales (incl. reinvestments): $78.5M
- Sales ÷ redemptions: 0.68×
| Month | Sales | Redemptions | Net flow |
|---|---|---|---|
| Jun 2026 | $9.4M | $9.4M | $19K |
| May 2026 | $0 | $3.7M | −$3.7M |
| Apr 2026 | $0 | $1.9M | −$1.9M |
| Mar 2026 | $25.8M | $25.4M | $365K |
| Feb 2026 | $1.9M | $3.9M | −$1.9M |
| Jan 2026 | $2.0M | $1.9M | $69K |
| Dec 2025 | $17.1M | $17.3M | −$191K |
| Nov 2025 | $5.7M | $3.8M | $2.0M |
| Oct 2025 | $0 | $20.9M | −$20.9M |
| Sep 2025 | $14.9M | $18.4M | −$3.5M |
| Aug 2025 | $1.7M | $0 | $1.7M |
| Jul 2025 | $0 | $8.2M | −$8.2M |
BBH Assets Under Management
Net assets of VanEck Biotech ETF by report date, from SEC N-PORT filings.
| Report date | Net assets |
|---|---|
| 2026-06-30 | $395.55M |
| 2026-03-31 | $371.59M |
| 2025-12-31 | $375.82M |
| 2025-09-30 | $347.33M |
| 2025-06-30 | $330.62M |
| 2025-03-31 | $365.94M |
| 2024-12-31 | $396.46M |
| 2024-09-30 | $451.99M |
| 2024-06-30 | $433.57M |
| 2024-03-31 | $452.51M |
| 2023-12-31 | $479.07M |
| 2023-09-30 | $450.98M |
For information only. Not investment advice: figures are as reported in SEC filings and may contain errors or be out of date. Past performance does not guarantee future results.